advanced medical technologies - Latest Comments

Re: Investment Upswing: medical technology fundings picking up pace

facebook-675628111 — Mon, 09 Nov 2009 17:14:00 -0000

Mentor Capital is well poised to become a significant participant in the expanding medical sector of Cancer Immunotherapy, an emerging approach to overcome the historic medical nemesis of Cancer. This is starting with MNTR's initial $2.2 million or 20% investment in Quantum Immunologics, Inc. (QI), a private company. The QI agreement contemplates "there is potential for significantly increased investment, or even merger of the Parties."

Re: Wound classification: Severity, Morphology, Etiology, Color

padraic526 — Sat, 10 Oct 2009 15:38:22 -0000

The report #S247, in addition to providing the data on products, technologies and markets, provides data on incidence and prevalence of the different wound types.

Re: Mechanisms of tissue repair and commercial development

padraic526 — Sat, 10 Oct 2009 15:25:41 -0000

See "Mechanisms of tissue repair and commercial development" from report #S175, http://mediligence.com/rpt/rpt-s175.htm

Re: http://mediligence.com/blog/2009/10/09/2037/

padraic526 — Sat, 10 Oct 2009 15:15:15 -0000

Global markets for wound management technologies, while demonstrating some predictable ways based on demographics, may vary considerably as the result of local clinical practice patterns and other drivers.

Re: Dynamic stabilization in spine surgery under the FDA’s scrutiny for postmarket surveillance

bron2k9 — Fri, 09 Oct 2009 13:35:26 -0000

Dynamic stabilization systems must undergo tighter scrutiny: http://www.newsinferno.com/archives/13230#more-...

Re: Advanced wound care technologies

Advanced_Scientifics — Tue, 15 Sep 2009 13:30:34 -0000

Thanks. I found this breakdown very interesting, especially the large increase in physical therapies. In addition to these expected changes, it should interesting to see emerging therapies as well.

Re: Investments and financings in medical technology reach $388 million for August 2009

padraic526 — Thu, 03 Sep 2009 11:14:12 -0000

The $20 million financing by iWalk pushed August 2009 medtech financings over $400 million. Of course, there is no particular significance in round numbers like "400", but as I look back over the challenges of financing in the last 8-10 months, it is clearly an advance in total financings when the number crosses $400 million.

Re: Investments and financings in medical technology reach $388 million for August 2009

padraic526 — Wed, 02 Sep 2009 00:45:13 -0000

It appears that the financing from Endosense, a $36 million Series B, just missed the Aug. 31 cutoff. Otherwise August medtech financings would have been in excess of $400 million.

Re: Minimally invasive spine surgery becoming technology-enabled

padraic526 — Tue, 25 Aug 2009 17:12:32 -0000

Indeed. I was still in the process of adding the exhibit from our prior spine surgery report and had not yet had a chance to add the footnote to the vertebroplasty data. Your comment beat me to it!

It is indeed striking that the procedure has apparently shown no advantage whatsover compared to controls. It perhaps speaks to the invasiveness of spine surgery, the associated trauma and the chronic pain issue of spine problems that a minimally invasive procedure gained a position without having the data to support an actual advantage over alternatives (or nothing at all).

Re: Minimally invasive spine surgery becoming technology-enabled

medical — Tue, 25 Aug 2009 16:38:16 -0000

Looks like Vertebroplasty just got blasted by the New England Journal of Medicine. They tested vertebroplasty in a far more rigorous way. They randomly assigned patients to get either vertebroplasty or a fake procedure in which patients were injected with local anesthetic but no cement. Researchers followed patients for a few months to see if there was any difference in pain or functioning. Guess what? "People who got a fake procedure did just as well as people who got the real thing".

Sometimes the shortest route is not the best route.

James Monroe

Re: (Relatively) slow start to August medtech financings

padraic526 — Tue, 18 Aug 2009 15:16:55 -0000

Add $1M for Flex Biomedical, $75M for ArthroCare, $1.6M for Embrella Cardiovascualar, $6M for M2Group Holdings, and $6.1M for BridgePoint Medical, bringing the August total now to $2-5.8 million.

Re: Degenerative disc diseases, implications for spinal surgery technolologies

spinalbypass — Sun, 16 Aug 2009 15:29:25 -0000

I have spinal stenosis resulting from an accident several years ago. When it first happened, I had major pain and buzzing in my foot and a feeling of paper cuts on my toes, and a pain like an ice pick behind my knee, but now the pain is mostly gone. I still have the stenosis however, according to the MRI.

Re: Drug-Eluting Stents’ New Growth and Opportunities: Any Doubts?

mdneymathali — Mon, 27 Jul 2009 06:43:47 -0000

today is the best drug eluting stent in the market is biomatrix DES which is a biosensors company product,because of biodegradable polymer and the drug which is Biolimas A9 drug.

Re: Stent shapes, designs and impact on restenosis, other complications

drkparikh — Sat, 18 Jul 2009 06:00:36 -0000

The strut thickness was a parameter which was a consideration for the BMS, but for DES apart from the stent the other important parameter is Polymer. It is a known fact that all the first generation DES are having the stable polymer which stays inside the body and it has been found to be the culprit behind the late and very late stent thrombosis by causing inflammation. The latest trend is to have a biodegradable polymer along with low strut thickness and in this there are quiet a few companies which have done quite a lot of research.
1. Sahajanand Medical Technologies , www.smtpl.com are the pioneers in this technology. Infinnium- paclitaxel eluting stent was the first to have a blend of biodegradable polymers. Infinnium infact happens to be the 1st stent with biodegradable polymers to get the CE approval. SMTPL has 3 more DES and all are with biodegradable polymers. many publications of SMTPLs DES shows consistent low Mace rates and Low Stent thrombosis Rates
2. Biosensors also has the Biomatrix stent with PLA as the biodegradable polymer. But Pla alone is not enough as the polymer is not very elastic and develops cracks easily and hence the chance of non uniform distribution of drug.
3. Termuo also has the NOBORI stent with just the Pla biodegradable polymer
4. JMD has the Excel stent with just the PLA biodegradable polymer.

the future can also see the success development of BIODEGRADABLE STENT. But this technology looks to be far away till that time Biodegradable polymer based DES will rule the market

Re: Worldwide coronary stents market

padraic526 — Wed, 24 Jun 2009 09:55:28 -0000

As a patient, you should only ask your doctor about specific manufacturers and their products, since different types and locations of occlusions, patient health status and other factors will determine the appropriate procedure and device. Also, don't assume that if you need angioplasty, you also need a stent.

Re: Worldwide coronary stents market

LincolnB — Wed, 24 Jun 2009 08:41:15 -0000

Ok, so I need to have an angioplasty. Should I request certain manufacturers for a stent?

Re: Medtronic is dead and all the innovation that goes with it (with me so far?)

David Locke — Mon, 22 Jun 2009 12:31:52 -0000

Sounds like Medtronic is stuck in a red ocean. The radical innovator at least has the advantage that there are no alternatives to their product.

There is another issue in regards to financing. Realize that a doctor's AR is not an asset that they can get financing on. They cannot factor their receivables, because of the discounting done by the insurance companies.

If healthcare has a problem, it is the insurance companies.

Re: Dynamic stabilization (posterior): interspinous process spacers in spine surgery

SGB — Sun, 21 Jun 2009 23:30:17 -0000

Thank You for this information. It might be life saving, in my personal quest to find out what the alternatives are, and who is working on them.

SGB

Re: Common threads in new medical technology development

Thom Ruhe — Wed, 10 Jun 2009 11:26:20 -0000

Excellent information! Thanks for posting.

Re: Medical technology platforms with high growth potential

neil p — Thu, 21 May 2009 13:58:01 -0000

Nicely written.

Re: Drug-Eluting Balloon Catheters

Dr. med. Alexander Ruebben — Tue, 05 May 2009 05:38:16 -0000

Now first Data from ELUTAX:

The IASIS-CE Register is a project for registering the use of ELUTAX on the coronary vessels and in-stent restenosis

30 Patients in instent Restenosis

6 months angiographic follow-up
0% Restenosis

Also Elutax release more than 75% of drug after first inflation!

Re: High strength medical glues and adhesives

Brad — Sat, 18 Apr 2009 01:48:33 -0000

interesting article. I sell ca glue and know of several instances of it being used for temporary emergency wound closure. I look forward to it becoming a common resource and satisfactory alternative to suturing!

Re: Meanwhile, American Medical Systems Corners a Market

Tue, 17 Mar 2009 15:47:15 -0000

AMS is not a laser company. Nor do they care to understand lasers or the market. Almost all of the Laserscope people are gone along with their expertise. Such a waste on money and talent.

Re: Of PMAs, Medtronic and, well, Medtronic

Will — Thu, 26 Feb 2009 22:21:58 -0000

Not at all... just trying to figure out what i was doing wrong. thanks!

Re: Of PMAs, Medtronic and, well, Medtronic

padraic526 — Thu, 26 Feb 2009 01:02:18 -0000

Sorry, but I still count 58. Are you looking at http://www.fda.gov/cdrh/pma/pmajan09.html?

And, in any event, this doesn't change the thrust of the point being made, does it?